Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
about
Novel Abetalipoproteinemia Missense Mutation Highlights the Importance of the N-Terminal β-Barrel in Microsomal Triglyceride Transfer Protein FunctionFamilial hypercholesterolemia: Review of diagnosis, screening, and treatmentNew drugs for treating dyslipidemia: beyond statinsNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaRole of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee RecommendationsFamilial hypercholesterolemia: developments in diagnosis and treatmentClinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BLiver histology during Mipomersen therapy for severe hypercholesterolemiaThe genetics of familial hypercholesterolemia and emerging therapiesFamilial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and ManagementMTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study.Stepping toward therapeutic CRISPR.Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingMy Approach to the Patient With Familial Hypercholesterolemia.Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan.Lipid pharmacotherapy for treatment of atherosclerosis.The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management.Ongoing challenges for pharmacotherapy for dyslipidemia.Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.Chylomicronaemia--current diagnosis and future therapies.Statin intolerance: diagnosis and remedies.PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Non-coding RNAs as drug targets.The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.Novel Therapies for Familial Hypercholesterolemia.Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.Lomitapide for the treatment of hypertriglyceridemia.The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.
P2860
Q24338622-A3D87DE5-81F2-47C2-81C2-8992EE424B8CQ26770143-E78728EA-54E3-4780-97E1-CD6570FD5189Q26821840-644C9EDF-A17B-4AA3-B206-23ADDF34D0D8Q28084156-A6331825-A309-4417-A5DF-B70B4E232887Q28275648-DBDD9787-F202-4603-A496-C72EC7B97B86Q29994487-1C8B5E57-D999-4ACD-AEF1-9B63B0C59288Q34106665-10855845-69A4-482A-A6D0-B7DDD7DDFE5AQ34456562-39E76D86-D6C7-45E0-8914-5F7F5D2BF351Q34718630-10486272-A9BA-478E-A1F9-6A47B9AFA33FQ35043485-FE044409-71FF-4BEC-8F66-B5D7552F65C0Q35756629-641CF0C4-6AB7-437C-B236-41947FF538F9Q35803568-7AC394B0-7DAB-4AD6-8EFE-3AF39036D98EQ36419830-20084F53-8316-42B1-B85F-53A7971599BEQ36665368-425FC10E-A00C-40B3-BD1B-49ED764564DEQ37731770-FF6EDDE6-8225-417F-8B5B-FBB2417CCC31Q37740339-88DC7E0F-EBA1-4BFA-A1E1-9DF42F7C97E5Q38202198-1112BAD4-1800-435F-A0F6-AAE42EE36CE2Q38268342-B833E444-AB04-4FC7-B41F-95B90A6FBC48Q38269470-D5EBD5E3-A4EC-43B3-B336-04ACD8E0FB34Q38283386-672496E5-30EF-46B2-BCE2-6B7EBEEAF24BQ38285812-1580B4D1-7CBF-4319-BE3C-A697BD5DC199Q38366873-127661DD-0CB3-4CC3-858F-78539D90A7E2Q38430744-45089DDE-0CCF-4C18-B5A9-D531E99E2D44Q38525880-DDDAF2B3-1A53-440A-BB89-0F34E4962899Q38546242-958D40A8-C753-4990-8589-E250BF95E1AEQ38589286-17B74C6D-BA38-4FBC-8683-1FFD81572C38Q38760884-37D09099-187F-4820-A822-E904647B18B3Q38889573-960F9F3E-9D67-4F7F-AC47-B5031AED052DQ38904908-ED8C498B-7B39-4BEF-A4BF-F3CACAD623BDQ38934039-CBA58D04-AC77-42D5-8617-204832306CE2Q38938935-FD9A8DAA-9F0B-4C1F-A847-813C9645C263Q38952663-FBFB164D-B049-4147-B68B-6AA318998F1DQ38968510-04E70E8C-7831-4D1F-8646-54C29FC7C09EQ38969073-0765434F-5B42-4846-A5FA-5B84150F466FQ38992251-0E99FC8E-A5FC-4D7A-8245-FEC4EF422E33Q39080645-73B5DA52-FF88-4BEA-8A01-9D98B9A89628Q39320394-2B342483-58A8-4950-AAD9-634C2FD74989Q39324079-F3458531-D760-40E1-838D-32BDCA79112BQ40102570-2177C2BE-204F-49D7-931A-11495777171CQ40104818-21DF1FEA-CE1D-4449-98EA-DDDC7003F454
P2860
Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@ast
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@en
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@nl
type
label
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@ast
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@en
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@nl
prefLabel
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@ast
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@en
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@nl
P921
P1433
P1476
Lomitapide and mipomersen: two ...... familial hypercholesterolemia.
@en
P2093
Daniel J Rader
John J P Kastelein
P304
P356
10.1161/CIRCULATIONAHA.113.001292
P407
P577
2014-03-01T00:00:00Z